ESR2 and adenocarcinoma: These data are important considering that similar alterations have been described for human prostate, in which ERβ is highly decreased in PIN areas and adenocarcinomas, reaching undetectable levels with the tumor progression, even though the receptor prevail in hyperplasic tissue [6, 7, 16, 17, 18, 19, 44].